Melanoma in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma

Famenini, Shannon; Martires, Kathryn J.; Zhou, Hui; Xavier, Marin; Wu, Jashin J.

doi:10.1016/j.jaad.2014.09.030

Cited by 36 publications

(35 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with CLL who have not received HCT have an increased incidence of melanoma and nonmelanoma skin cancers and a greater risk of advanced disease, metastases, and recurrence (Brewer et al, 2010;Brewer et al, 2012;Brewer et al, 2015a;Brewer et al, 2015b;Famenini et al, 2015;Mehrany et al, 2004;Mehrany et al, 2005;Velez et al, 2014). We identified CLL as an independent additional significant risk factor for increased incidence of all skin cancers, SCCs, and BCCs in our cohort of HCT patients.…”

Section: Discussionmentioning

confidence: 75%

Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell Transplantation

Stern

Huang

et al. 2019

Journal of Investigative Dermatology

View full text Add to dashboard Cite

To assess incidence and risk factors for skin cancer associated with allogeneic hematopoietic stem cell transplantation, we evaluated 1,974 adult allogeneic hematopoietic stem cell transplantation patients from Beth Israel Deaconess Medical Center and Dana-Farber Cancer Institute who received transplants between January 1995 and July 2013 for hematologic malignancy and survived at least 100 days. Median age was 51.1 years, and median follow-up time was 3 years. Overall, 119 patients had 221 skin cancers. The incidences of squamous cell carcinomas (incidence rate ratio ¼ 9.8; 95% confidence interval ¼ 7.7e12.3), basal cell carcinomas (incidence rate ratio ¼ 2.5; 95% confidence interval ¼ 1.9e3.2), and melanoma (standardized incidence ratio ¼ 3.3; 95% confidence interval ¼ 1.7e5.9) were elevated in our cohort. In multivariable models, risk factors for squamous cell carcinomas were increased age (P < 0.0001), chronic lymphocytic leukemia (P ¼ 0.02), and chronic graftversus-host disease (P ¼ 0.0002). Risk factors for basal cell carcinomas were chronic lymphocytic leukemia (P ¼ 0.003), reduced-intensity conditioning (P ¼ 0.02), acute graft-versus-host disease (P ¼ 0.03), and chronic graft-versus-host disease (P ¼ 0.003). To our knowledge, previously unreported risk factors in this contemporary cohort include prior CLL for squamous cell carcinoma and basal cell carcinoma and reduced-intensity conditioning for basal cell carcinoma. This study also supports chronic graft-versus-host disease as a risk factor for nonmelanoma skin cancer, particularly squamous cell carcinoma.

show abstract

Section: Discussionmentioning

confidence: 75%

Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell Transplantation

Stern

Huang

et al. 2019

Journal of Investigative Dermatology

View full text Add to dashboard Cite

show abstract

“…13 The likely mechanism for these increased risks is multifactorial, with environmental factors (i.e., smoking), immunodeficiency from hematologic malignancies, and shared genetic mutations contributing to the same. [17][18][19] Other studies have found more equivocal results. A French population-based study found no increased risk for nonmelanoma SPM in cutaneous MM survivors (SIR = 1.0).…”

Section: Discussionmentioning

confidence: 95%

“…In addition to an increased risk for cancer of the thyroid and kidney in cutaneous MM survivors, an increased risk for lymphoid and hematopoietic system malignancy in cutaneous MM survivors has been reported, showing an increased risk for NHL, acute myeloid leukemia (AML), and CLL . The likely mechanism for these increased risks is multifactorial, with environmental factors (i.e., smoking), immunodeficiency from hematologic malignancies, and shared genetic mutations contributing to the same …”

Section: Discussionmentioning

confidence: 99%

Risks for noncutaneous second primary malignancy in cutaneous malignant melanoma survivors: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) program

et al. 2020

View full text Add to dashboard Cite

Background It is known that malignant melanoma (MM) survivors are at increased risk of future primary MM. However, the risk for noncutaneous second primary malignancies (SPMs) is not as well‐understood. Methods An observational study utilizing data from the Surveillance, Epidemiology, and End Results (SEER) database was performed, assessing data from patients diagnosed with primary cutaneous MM to measure overall, as well as specific, tumor type and risk of SPM. Results Of the 132,438 patients recruited in the study population (mean age 55.5 years; 54% male), 23,794 SPMs were observed (O) (18% of patients at a mean age of 68.8 years), while 17,923 SPMs were expected (E) to occur (O : E 1.33, 95% CI 1.31–1.34). Excluding cutaneous MM occurring as a new primary malignancy, there was a significantly increased risk for SPMs among cutaneous MM survivors for each of the following tumor types: eye and orbit melanoma, tracheal, thyroid, salivary gland, retroperitoneum, small intestine, kidney, lymphoid and hematopoietic system, lymphoma overall, non‐Hodgkin lymphoma, lymphocytic leukemia overall, chronic lymphocytic leukemia, male genital system (including prostate), and breast. Certain gender‐specific trends for SPMs were also detected. Conclusions Patients with primary cutaneous MM are at increased risk for primary noncutaneous MM as well as noncutaneous SPMs that include numerous tumor types. Enhanced oncologic surveillance for a variety of tumor types in melanoma survivors is warranted.

show abstract

“…Interestingly, patients diagnosed with CLL are at two-fold to four-fold increased risk of developing melanoma(37, 38). Although this increased risk has been primarily attributed to the immunosuppressive effect of CLL, a common genetic etiology involving telomere lengthening may also contribute.…”

Section: Discussionmentioning

confidence: 99%

Genetic Variation Associated with Longer Telomere Length Increases Risk of Chronic Lymphocytic Leukemia

Ojha

Codd

Nelson

et al. 2016

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world. Shorter mean telomere length in leukemic cells has been associated with more aggressive disease. Germline polymorphisms in telomere maintenance genes impact telomere length and may contribute to CLL susceptibility. Methods We collected genome-wide data from two groups of patients with CLL (N=273) and two control populations (N=5725). In ancestry-adjusted case-control comparisons, we analyzed eight single nucleotide polymorphisms (SNPs) in genes definitively associated with inter-individual variation in leukocyte telomere length (LTL) in prior genome-wide association studies: ACYP2, TERC, NAF1, TERT, OBFC1, CTC1, ZNF208, and RTEL1. Results Three of the eight LTL-associated SNPs were associated with CLL risk at P<0.05, including those near: TERC (O.R.=1.46; 95% C.I.=1.15–1.86; P=1.8×10−3), TERT (O.R.=1.23; 95%C.I.=1.02–1.48; P=0.030), and OBFC1 (O.R.=1.36; 95%C.I.=1.08–1.71; P=9.6×10−3). Using a weighted linear combination of the 8 LTL-associated SNPs, we observed that CLL patients were predisposed to longer LTL than controls in both case-control sets (P=9.4×10−4 and 0.032, respectively). CLL risk increased monotonically with increasing quintiles of the weighted linear combination. Conclusions Genetic variants in TERC, TERT, and OBFC1 are associated with both longer LTL and increased CLL risk. Because the human CST complex competes with shelterin for telomeric DNA, future work should explore the role of OBFC1 and other CST complex genes in leukemogenesis. Impact A genetic predisposition to longer telomere length is associated with an increased risk of CLL, suggesting that the role of telomere length in CLL etiology may be distinct from its role in disease progression.

show abstract

Melanoma in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma

Cited by 36 publications

References 33 publications

Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell Transplantation

Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell Transplantation

Risks for noncutaneous second primary malignancy in cutaneous malignant melanoma survivors: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) program

Genetic Variation Associated with Longer Telomere Length Increases Risk of Chronic Lymphocytic Leukemia

Contact Info

Product

Resources

About